Company intelligence / Profile preview

ChemPrint

San Francisco, California, USA

Ownership: Private
Employees: ~10
Development stage: Other

Overview

ChemPrint is an early-stage biotechnology company developing a proprietary 3D printing platform for the pharmaceutical industry. The company's technology aims to automate the synthesis and formulation of personalized medicines, allowing for the creation of customized dosage forms with precise release profiles and multi-drug combinations. Founded by veterans of the 3D printing drug industry, ChemPrint seeks to enable on-demand manufacturing at the point of care or in specialized facilities. By transforming traditional pharmaceutical manufacturing into a digital, decentralized process, the company aims to improve patient adherence and therapeutic outcomes for complex dosing regimens.

Therapeutic areas: Rare DiseasesOther
Modalities: Small molecule3D-printed dosage forms
Industry: Drug Discovery Services

Beyond the preview

Go deeper on ChemPrint.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChemPrint.

Explore the full profile